Investors with a lot of money to spend have taken a bullish stance on Liquidia LQDA.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LQDA, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 8 uncommon options trades for Liquidia.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $59,125, and 6 are calls, for a total amount of $273,671.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $12.5 for Liquidia during the past quarter.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Liquidia's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Liquidia's significant trades, within a strike price range of $7.5 to $12.5, over the past month.
Liquidia Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| LQDA | CALL | TRADE | BEARISH | 02/16/24 | $7.50 | $101.9K | 1.0K | 201 |
| LQDA | CALL | TRADE | BEARISH | 02/16/24 | $7.50 | $50.0K | 1.0K | 301 |
| LQDA | CALL | SWEEP | BEARISH | 04/19/24 | $12.50 | $45.2K | 5.3K | 284 |
| LQDA | PUT | SWEEP | BULLISH | 02/16/24 | $12.50 | $34.1K | 1.2K | 331 |
| LQDA | CALL | TRADE | BULLISH | 03/15/24 | $7.50 | $25.9K | 488 | 683 |
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
In light of the recent options history for Liquidia, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Liquidia's Current Market Status
- With a trading volume of 1,742,312, the price of LQDA is down by -7.63%, reaching $11.14.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 49 days from now.
What Analysts Are Saying About Liquidia
1 market experts have recently issued ratings for this stock, with a consensus target price of $28.0.
- An analyst from Needham persists with their Buy rating on Liquidia, maintaining a target price of $28.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Liquidia options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
